scorecardresearch
Add as a preferred source on Google
Friday, December 12, 2025
TopicDCGI

Topic: DCGI

Delhi HC orders examination into weight loss drug combinations, asks DCGI to seek expert consultation

The proceedings follow a PIL seeking a ban on sale of weight loss drugs that are still undergoing clinical trials internationally. The court asked DCGI to submit report within 3 months.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

‘Unauthorised promotion’, risk of unsafe use: Why CDSCO revoked nod for eye drops to replace glasses

Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.

Why apex ophthalmologists’ body wants to review new eye drops designed to replace reading glasses

All India Ophthalmological Society has set up expert group to review PresVu & develop guidelines on side-effects, keeping in mind 'potential inappropriate marketing, indiscriminate use'.

Launched in India: eye drop that can replace your reading glasses

Launched Tuesday by Entod Pharmaceuticals under brand name PresVu, eye drop will treat presbyopia, an age-related condition causing blurry vision. To be available across India by October.

Govt notifies rule for rapid launch of breakthrough drugs in India, bypassing local clinical trials

In an executive order, the DGCI has specified a list of countries under rule 101 of New Drugs and Clinical Trials Rules, 2019. List includes US, UK & EU, among others.

Breakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod

Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.

Calls for caution over phenylephrine’s efficacy, as FDA panel deems decongestant ineffective

Panel report notes that oral phenylephrine is no better than placebo for relieving nasal congestion. In India, phenylephrine is widely used in cough and cold medicines.

Kerala doctors & researchers plan India’s 1st private drug quality assessment drive

Project follows outcry over NMC rule, now on hold, asking medical practitioners to prescribe generics or face penalty. Dr Cyriac Abby Philips or ‘@TheLiverDoc’ part of project.

On Camera

IndiGo cancellations made TV news do the unexpected — question the Modi government

Republic TV was the harshest of them all: “The (civil aviation) minister has done a bad job,” said prime time anchor Arnab Goswami.

IndiGo’s profits dipped, most airlines sunk into losses last fiscal even as flier numbers soared

Despite growing passenger volume, 11 out of 14 carriers reported losses in 2023-24. IndiGo recorded profit of Rs 8,167 crore, which reduced to Rs 7.253 crore in 2024-25.

US clears $686-mn package to breathe fresh life into Pakistani F-16s

Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).

Asim Munir & Pakistan’s Failed Marshal Doctrine

None of Pakistan’s PMs has lasted 5 years. That the current PM has given Asim Munir 5 years shows that of all military dictatorships history has seen, Pakistan’s is most creative.